Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream

C. William Hanke, Neil Swanson, Suzanne Bruce, Brian Berman, James Kulp, Sharon Levy

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Assess long-term, sustained, complete clearance of actinic keratoses after treatment with imiquimod 3.75% or 2.5% cream using two two-week or three-week cycles of daily dosing. Methods: Adults with five to 20 baseline actinic keratoses who achieved complete clearance at the eight-week post-treatment visit in four phase 3 placebo-controlled treatment studies were followed for an additional 12 months. Results: For imiquimod 3.75% and 2.5% cream, respectively, complete clearance was sustained for 12 months in 17/42 (40.5%) and 13/39 (33.3%) subjects from the two-week cycle studies, and in 23/48 (47.9%) and 16/37 (43.2%) subjects from the three-week cycle studies. There were no safety concerns during the follow-up. Conclusion: In subjects with a median of eight to nine baseline actinic keratoses who achieved complete clearance after treatment of the full face or balding scalp with topical imiquimod 3.75% cream, complete clearance of all lesions (baseline, recurrent or new) was sustained in ≥40 percent of subjects for at least 14 months after the last dose. Clinicaltrials.gov identifier NCT00668733.

Original languageEnglish (US)
Pages (from-to)165-170
Number of pages6
JournalJournal of Drugs in Dermatology
Volume10
Issue number2
StatePublished - Feb 2011

Fingerprint

imiquimod
Actinic Keratosis
Scalp
Therapeutics
Placebos
Safety

ASJC Scopus subject areas

  • Dermatology

Cite this

Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. / Hanke, C. William; Swanson, Neil; Bruce, Suzanne; Berman, Brian; Kulp, James; Levy, Sharon.

In: Journal of Drugs in Dermatology, Vol. 10, No. 2, 02.2011, p. 165-170.

Research output: Contribution to journalArticle

Hanke, C. William ; Swanson, Neil ; Bruce, Suzanne ; Berman, Brian ; Kulp, James ; Levy, Sharon. / Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. In: Journal of Drugs in Dermatology. 2011 ; Vol. 10, No. 2. pp. 165-170.
@article{207e712043324f34859f9cf0fb78dabe,
title = "Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75{\%} or 2.5{\%} cream",
abstract = "Objective: Assess long-term, sustained, complete clearance of actinic keratoses after treatment with imiquimod 3.75{\%} or 2.5{\%} cream using two two-week or three-week cycles of daily dosing. Methods: Adults with five to 20 baseline actinic keratoses who achieved complete clearance at the eight-week post-treatment visit in four phase 3 placebo-controlled treatment studies were followed for an additional 12 months. Results: For imiquimod 3.75{\%} and 2.5{\%} cream, respectively, complete clearance was sustained for 12 months in 17/42 (40.5{\%}) and 13/39 (33.3{\%}) subjects from the two-week cycle studies, and in 23/48 (47.9{\%}) and 16/37 (43.2{\%}) subjects from the three-week cycle studies. There were no safety concerns during the follow-up. Conclusion: In subjects with a median of eight to nine baseline actinic keratoses who achieved complete clearance after treatment of the full face or balding scalp with topical imiquimod 3.75{\%} cream, complete clearance of all lesions (baseline, recurrent or new) was sustained in ≥40 percent of subjects for at least 14 months after the last dose. Clinicaltrials.gov identifier NCT00668733.",
author = "Hanke, {C. William} and Neil Swanson and Suzanne Bruce and Brian Berman and James Kulp and Sharon Levy",
year = "2011",
month = "2",
language = "English (US)",
volume = "10",
pages = "165--170",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "2",

}

TY - JOUR

T1 - Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream

AU - Hanke, C. William

AU - Swanson, Neil

AU - Bruce, Suzanne

AU - Berman, Brian

AU - Kulp, James

AU - Levy, Sharon

PY - 2011/2

Y1 - 2011/2

N2 - Objective: Assess long-term, sustained, complete clearance of actinic keratoses after treatment with imiquimod 3.75% or 2.5% cream using two two-week or three-week cycles of daily dosing. Methods: Adults with five to 20 baseline actinic keratoses who achieved complete clearance at the eight-week post-treatment visit in four phase 3 placebo-controlled treatment studies were followed for an additional 12 months. Results: For imiquimod 3.75% and 2.5% cream, respectively, complete clearance was sustained for 12 months in 17/42 (40.5%) and 13/39 (33.3%) subjects from the two-week cycle studies, and in 23/48 (47.9%) and 16/37 (43.2%) subjects from the three-week cycle studies. There were no safety concerns during the follow-up. Conclusion: In subjects with a median of eight to nine baseline actinic keratoses who achieved complete clearance after treatment of the full face or balding scalp with topical imiquimod 3.75% cream, complete clearance of all lesions (baseline, recurrent or new) was sustained in ≥40 percent of subjects for at least 14 months after the last dose. Clinicaltrials.gov identifier NCT00668733.

AB - Objective: Assess long-term, sustained, complete clearance of actinic keratoses after treatment with imiquimod 3.75% or 2.5% cream using two two-week or three-week cycles of daily dosing. Methods: Adults with five to 20 baseline actinic keratoses who achieved complete clearance at the eight-week post-treatment visit in four phase 3 placebo-controlled treatment studies were followed for an additional 12 months. Results: For imiquimod 3.75% and 2.5% cream, respectively, complete clearance was sustained for 12 months in 17/42 (40.5%) and 13/39 (33.3%) subjects from the two-week cycle studies, and in 23/48 (47.9%) and 16/37 (43.2%) subjects from the three-week cycle studies. There were no safety concerns during the follow-up. Conclusion: In subjects with a median of eight to nine baseline actinic keratoses who achieved complete clearance after treatment of the full face or balding scalp with topical imiquimod 3.75% cream, complete clearance of all lesions (baseline, recurrent or new) was sustained in ≥40 percent of subjects for at least 14 months after the last dose. Clinicaltrials.gov identifier NCT00668733.

UR - http://www.scopus.com/inward/record.url?scp=80052054177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052054177&partnerID=8YFLogxK

M3 - Article

C2 - 21283921

AN - SCOPUS:80052054177

VL - 10

SP - 165

EP - 170

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 2

ER -